Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SHANGHAI, China and PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other...
-
中国上海和美国普林斯顿, April 15, 2022 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN），一家专注于为中国和亚洲主要市场的患者带来创新性药物的生物科技公司，今日宣布成立科学顾问委员会（Scientific Advisory...
-
SHANGHAI AND PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) announced today that its partner, ReViral Ltd., is expected to be acquired by Pfizer Inc. (NYSE: PFE). LianBio...
-
中国上海和美国普林斯顿, April 07, 2022 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN），一家专注于为中国和亚洲主要市场的患者带来创新性药物的生物科技公司，今日宣布任命陈维维女士担任公司董事会成员。 ...
-
SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian...
-
Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for...
-
Mavacamten用于治疗中国有症状的梗阻性肥厚型心肌病患者的3期注册试验正在进行用于治疗梗阻性肥厚型心肌病的mavacamten在中国获得“突破性治疗药物”认证英菲格拉替尼在海南博鳌先行区获批用于治疗胆管癌患者三个其他产品管线项目预计将在2022年底前在中国启动3期注册临床试验4.032亿美元现金储备足以维持至2023年的营业需求 中国上海和美国普林斯顿, March 31, 2022 ...
-
中国上海和美国普林斯顿, March 12, 2022 (GLOBE NEWSWIRE) --...
-
SHANGHAI and PRINCETON, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Following the Determination Report of the Public Company Accounting Oversight Board (“PCAOB”) issued on December 16, 2021, on March...
-
SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian...